Matthew J Ellis MD PhD FRCP

Breast Cancer, Hematologic Oncology

Director, Lester and Sue Smith Breast Center Baylor College of Medicine, Professor of Medicine and Molecular Cell Biology, associate director, translational research Dan L Duncan Comprehensive Cancer Center

Join to View Full Profile

6620 Main StHouston, TX 77030
Phone+1 713-798-1999
Fax+1 713-798-1990

Education & Training

MedStart Georgetown University HospitalFellowship, Medical Oncology, 1992 - 1994
School of Clinical Medicine, University of CambridgeClass of 1983

Certifications & Licensure

TX State Medical License 2014 - 2022
MO State Medical License 2003 - 2015
NC State Medical License 2001 - 2005
DC State Medical License 1996 - 2004
MD State Medical License 1995 - 1996

Awards, Honors, & Recognition

CMS Meaningful Use Stage 1 Certification Allscripts Enterprise EHR, Allscripts, 2012

Clinical Trials

Letrozole, Herceptin in Her2neu +, Estrogen Receptor [ER] and/or Progesterone Receptor [PR] Positive, MBC Start of enrollment: 2000 Jan 01
Completed
Phase 2
Study of Physiological and High Dose Estradiol in the Treatment of Hormone Receptor Positive Metastatic Breast Cancer Start of enrollment: 2004 Aug 01
Completed
Phase 2
Effect of Neoadjuvant or Adjuvant Systemic Therapy on Breast Cancers, Bone Marrow Cancer Cells, and Circulating Cancer Cells Start of enrollment: 2005 Sep 14
RECRUITING
Combination Chemotherapy and Paclitaxel Plus Trastuzumab in Treating Women With Palpable Breast Cancer That Can Be Removed by Surgery Start of enrollment: 2007 Jul 01
Completed
Phase 3
Azacitidine and Entinostat in Treating Patients With Advanced Breast Cancer Start of enrollment: 2011 Aug 15
COMPLETED
PHASE2
Combining MLN8237 With Nab-Paclitaxel in Patients With Advanced Solid Malignancies Start of enrollment: 2013 May 07
Completed
Phase 1
PD 0332991 and Anastrozole for Stage 2 or 3 Estrogen Receptor Positive and HER2 Negative Breast Cancer Start of enrollment: 2013 Apr 10
ACTIVE_NOT_RECRUITING
PHASE2
LDE225 in Treating Patients With Stage II-III Estrogen Receptor- and HER2-Negative Breast Cancer Start of enrollment: 2014 Apr 01
Withdrawn
Phase 2
Effect of Trastuzumab on Disease Free Survival in Early Stage HER2-Negative Breast Cancer Patients With ERBB2 Expressing Disseminated Tumor Cells Start of enrollment: 2013 Dec 19
Terminated
Phase 2
VEGFR/PDGFR Dual Kinase Inhibitor X-82 and Everolimus for Treating Patients With Pancreatic Neuroendocrine Tumors Start of enrollment: 2013 May 03
Terminated
Phase 1, Phase 2
Neoadjuvant Treatment of Triple Negative Breast Cancer Patients With Docetaxel and Carboplatin to Assess Anti-tumor Activity Start of enrollment: 2014 Jul 07
Terminated
Phase 2
Join now to see all

Publications & Presentations

PubMed

Increased Synthetic Cytotoxicity of Combinatorial Chemoradiation Therapy in Homologous Recombination Deficient Tumors.
Jennifer Ma, Rachna Shah, Andrew C Bell, Niamh McDermott, Xin Pei
International Journal of Radiation Oncology, Biology, Physics. 2025-03-01
1 citations
Patient-Derived Xenografts of Triple-Negative Breast Cancer Enable Deconvolution and Prediction of Chemotherapy Responses.
Jonathan T Lei, Lacey E Dobrolecki, Chen Huang, Ramakrishnan R Srinivasan, Suhas V Vasaikar
Biorxiv. 2025-01-08
8 citations
IRE1α silences dsRNA to prevent taxane-induced pyroptosis in triple-negative breast cancer.
Longyong Xu, Fanglue Peng, Qin Luo, Yao Ding, Fei Yuan
Cell. 2024-12-12

Journal Articles

Proteogenomic Integration Reveals Therapeutic Targets in Breast Cancer Xenografts
Souzan Sanati, Jana W Qiao, Xian Chen, Matthew J Ellis, Cynthia Ma, Nature

Press Mentions

SABCS 2022: Panelists Discuss Strategies to Overcome Top Obstacles in Breast Cancer ManagementDecember 15th, 2022
Breast Cancer Test’s Genomic Underpinning Drives Prognostic PerformanceOctober 30th, 2020
Micro-Scaled Method Holds Promise as Improved Cancer Diagnostic PlatformJanuary 27th, 2020
Join now to see all